



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

000500 HM12/0716
SEED INTELLECTUAL PROPERTY LAW GROUP PLL
701 FIFTH AVE
SUITE 6300
SEATTLE WA 98104-7092

07/16/01

APPLICATION NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
09/439,313	11/12/99	005	ZHOU, S	1631 07/16/01
First Named Applicant	DILLON, 35 USC 154(b) term ext. = 0 Days.			

TITLE OF INVENTION COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF PROSTATE CANCER

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEES DUE	DATE DUE
0 210121.427C9	530-350.000	J13	UTILITY	NO	\$1240.00	10/16/01

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.

HOW TO RESPOND TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or

B. If the status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO:

A. Pay FEE DUE shown above, or

B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.

II. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give application number and batch number.

Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PATENT AND TRADEMARK OFFICE COPY

Notice of Allowability	Application No.	Applicant(s)
	09/439,313	XU ET AL.
	Examiner Shubo "Joe" Zhou	Art Unit 1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to Papers #9 and 14, filed on 5/2/01 and 6/20/01, respectively.
2. The allowed claim(s) is/are 66-70; renumbered as 1-5, respectively.
3. The drawings filed on _____ are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - (a) The translation of the foreign language provisional application has been received.
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. CORRECTED DRAWINGS must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No. _____.
 - (b) including changes required by the proposed drawing correction filed _____, which has been approved by the Examiner.
 - (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1 <input type="checkbox"/> Notice of References Cited (PTO-892) 3 <input checked="" type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) 5 <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449), <u>Examiner's Comment</u> <i>6 sheets</i> 7 <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material	2 <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) 4 <input checked="" type="checkbox"/> Interview Summary (PTO-413), Paper No. <u>15</u> . 6 <input checked="" type="checkbox"/> Examiner's Amendment/Comment 8 <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance 9 <input type="checkbox"/> Other
--	---

Examiner's Amendment

Applicants' election of Group I (original claims 1-3, 14-17, and 64) and SEQ ID NO:113, in Paper No. 9, filed 5/2/01, is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Applicants' amendment of canceling claims 1-3, 14-17, and 64, and adding claims 80-89 in Paper No.14, filed 6/20/01 is acknowledged and entered.

The numbering of claims is not in accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not).

Misnumbered claims 80-89 have been renumbered 65-74. Please note that the following refers to these claims by the renumbered claim number.

The newly added claims 71-74 are drawn to compositions comprising the claimed polypeptides and other immune response enhancer, which is not the elected subject matter.

During an telephone conversation with Jane Potter on 7/10/01, applicants deleted claim 65 (original claim 80).

Accordingly, claims 1-3, 14-17, and 64-65 have been canceled, claims 4-13, 18-63, and 71-74 are withdrawn from further consideration as being drawn to non-elected inventions. Currently, only claims 66-70 are under consideration by the Examiner.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in the 7/10/01 telephone interview between Jane Potter and the Examiner.

In the claims:

Cancel claims 4-13, 18-63, and 74-74.

In claim 66:

Delete line 1 and line 2, and replace with "An isolated polypeptide comprising at least a portion of SEQ ID NO:113, wherein said portion is selected from the group consisting of SEQ ID NOs: 554, 558 and 562."

In claim 67:

Line 2, after "identity to", insert --the entirety of--.

In claim 68:

Line 2, after "identity to a sequence", delete "recited in any one of SEQ ID NO", and insert therefore --selected from the group consisting of SEQ ID

NOs--.

In claim 69:

Line 2, after "identity to", insert --the entirety of--.

In claim 70:

Line 2, after "identity to a sequence", delete "recited in any one of SEQ ID NO", and insert therefor -selected from the group consisting of SEQ ID

C3

NOs--.

In the specification:

On page 8, line 5, after "22q11.2", insert ---.

On page 8, after line 5, insert the following paragraph:

C3

--Figure 11 shows the specificity of rabbit polyclonal antibodies against fragments of P501S by Elisa assay.--

On page 133, delete lines 1-4 containing "COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF PROSTATE CANCER".

Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The claimed invention is directed to isolated polypeptides comprising the sequence of SEQ ID NO:113, or any one of SEQ ID Nos: 554, 558, 562, 566 and 573. These polypeptides are prostate specific and over-expressed in prostate compared to all other normal tissues. The closest prior art is Riesmeier et al. (PIR database sequence JQ2389, 10/7/1997) who disclose a protein comprising a sequence having

only 11.5% identity to the sequence of SEQ ID NO:113, and the protein is not prostate-specific as required in the instant invention.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CFR § 1.6(d)). The CM1 Fax Center number is either (703) 308-4242 or (703)305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to:
Shubo "Joe" Zhou, Ph.D., whose telephone number is (703) 605-1158. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, Ph.D., can be reached on (703) 308-4028.

Any inquiry of a general nature or relating to the status of this application should be directed to Patent Analyst Tina Plunkett whose telephone number is 703)-305-3524, or to the Technical Center receptionist whose telephone number is (703) 308-0196.

805
S. "Joe" Zhou, Ph.D.
Patent Examiner

Ardin H. Marschel
ARDIN H. MARSCHEL
PRIMARY EXAMINER